Personalized Stem Cells’ New Trial Tests Adipose Stem Cell Therapy for Chronic Mild Traumatic Brain Injury
The pilot will evaluate intravenous PSC-05 in people with persistent symptoms after chronic mild traumatic brain injury, tracking adverse events and post-concussive symptoms through Day 90.

Personalized Stem Cells, Inc. is sponsoring a Phase 1 pilot study of PSC-05 in people with persistent symptoms after mild traumatic brain injury. The investigational therapy uses stem cells grown from each participant’s own fat tissue and is given by intravenous injection.
Through day 90, researchers will track adverse events starting at enrollment and assess post-concussion symptoms starting on the day of treatment using the Neurobehavioral Symptom Inventory.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
- Sponsor: Personalized Stem Cells, Inc.
- Phase/Status: Phase 1, enrolling by invitation
- Indication: Mild traumatic brain injury with persistent neurobehavioral symptoms related to chronic mTBI; planned enrollment of 10 participants
- Arms/Dosing: Investigational arm receives PSC-05, an autologous adipose-derived stem cell therapy product given as an intravenous injection of culture-expanded adipose stem cells
- Control: None
- Endpoints: Primary: adverse event rate from enrollment to Day 90, end of study. Secondary: Neurobehavioral Symptom Inventory measure of post-concussive symptoms from treatment Day 0 to Day 90, end of study
- Timing: Actual start November 1, 2026; estimated primary completion May 31, 2027; estimated study completion July 31, 2027
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
New Trial – Phase II Umbilical-Cord Stem Cells for Amyotrophic Lateral Sclerosis
New Trial – Intranasal Stem Cells for Perinatal Brain Injury and Cerebral Palsy
Mesenchymal Stem Cell Extracellular Vesicles Reprogram Microglia and Prevent Neurodegeneration in Alzheimer’s Models
Kangstem Biotech Reports Positive Phase 2a Results for Stem Cell Knee Osteoarthritis Therapy
CellFiber Opens First International Subsidiary in Philadelphia to Support Cell and Gene Therapy Development
Evia Bio Announces Availability of GMP-Grade DMSO-Free Cryopreservation Media for Mesenchymal Stromal Cells
Porton Advanced Announces FDA Acceptance of Drug Master File for Umbilical Cord Stem Cell-Derived Exosomes
INmune Bio and Uniphar Team Up to Support International Access to Umbilical Cord-Derived Cell Therapy for RDEB







